search icon
      blog search icon

      What Motivated VTVT Stock To Climb 20% Premarket? - Stocks Telegraph

      By ST Staff

      Published on

      June 22, 2021

      1:18 PM UTC

      Last Updated on

      July 14, 2021

      8:54 AM UTC

      What Motivated VTVT Stock To Climb 20% Premarket? - Stocks Telegraph

      The stock of vTv Therapeutics Inc. (VTVT) increased 19.92% to $2.83 at the last check in premarket trades today. The price of the stock dropped -3.28% to $2.36 at the end of the last trading session during which VTVT stock has traded between $2.32 and $2.422. A total of 0.74 million shares were traded, which was below the daily average of 5.21 million shares over the past 100 days.

      A look at the last five days of trading for VTVT shares shows a loss of -11.61%, while the last month shows a decline of -7.81%. As a result of announcing a strategic licensing agreement for the development and commercialization of azeliragon in cancer treatment, VTVT stock has increased.

      Who has VTVT signed a licensing agreement with?

      vTv Therapeutics is a clinical-stage biopharma company developing small molecule drugs for oral administration. Clinical trials for type 1 diabetes and psoriasis are at the forefront of VTVT’s pipeline of approved drugs. Additional indications for VTVT being pursued by its development partners include diabetes type 2, chronic obstructive pulmonary disease, renal disease, as well as primary mitochondrial myopathies.

      A licensing agreement was announced today between VTVT and Cantex Pharmaceuticals.

      • VTVT granted Cantex exclusive worldwide rights to develop and market azeliragon, which is VTVT’s new RAGE antagonist.
      • RAGE encodes the receptor for advanced glycation endproducts.
      • VTVT’s RAGE has been associated with a number of serious cancer complications that increase mortality and decrease quality of life.
      • With deep expertise and an extensive track record of successful drug development projects, Cantex can successfully turn known medicines into innovative products with wide clinical and commercial potential.
      • Cantex is therefore well suited to develop Azeliragon.
      • Aszeliragon is a phase 2-ready oral medication that is administered once daily and has been shown to be safe in several Alzheimer’s trials.
      • Cantex plans to move quickly to prepare for clinical trials that assess azeliragon’s potential for treating cancer-related complications.
      • VTVT’s RAGE is an intriguing target for treating many different disorders.
      • Azeliragon, which VTVT has studied for Alzheimer’s disease, is a perfect candidate for use in new therapeutic indications.
      • VTVT considers Cantex as a suitable partner for such development.
      • The companies will use a tiered arrangement to allocate downstream profits as Cantex is responsible for developing and commercializing azeliragon.

      VTVT’s other milestones:

      Based on vTv Therapeutics (VTVT)’s recent announcement, the Food and Drug Administration (FDA) has designated TTP399 as a Breakthrough Therapy for the treatment of type 1 diabetes. The novel glucokinase activator TTP399 was developed by VTVT for oral administration once daily.

      More From Stocks telegraph